Digital Health, Technology & Innovation

Wenzel Spine Launches Expandable panaSIa™ SI Fusion System

Wenzel Spine, Inc., a medical device company pioneering minimally invasive surgical and analytic solutions for spinal disorders, today announced completion of first cases and the U.S. limited commercial launch of its novel panaSIa™ Expandable SI Fusion System. panaSIa is the first expandable sacroiliac (SI) fusion implant cleared by the FDA and represents a major breakthrough in addressing sacroiliac joint dysfunction with enhanced biomechanical stability and procedural efficiency.

Designed to be implanted using a posterior, minimally invasive technique, panaSIa provides joint fixation through controlled expansion across the ilium and sacrum, offering immediate mechanical stability while preserving surrounding tissue. The implant’s integrated graft chamber allows for post-expansion bone grafting without disengaging instrumentation, facilitating optimal fusion conditions and minimizing procedural complexity.

The first U.S. procedures are part of a limited commercial release taking place at select surgical centers ahead of full launch in Q4 2025.

“panaSIa is unlike any SI fusion device currently available,” said Aaron Calodney, MD, a nationally recognized leader in interventional pain medicine. “The implant expands to eliminate micro-motion, providing immediate stabilization. By slightly distracting the joint space, it may reduce pain by removing contact between the arthritic surfaces. It’s simple, elegant, and biomechanically sound—a truly next-generation solution for SI joint fusion.”

The panaSIa system expands Wenzel Spine’s portfolio of stand-alone expandable fusion technologies and reflects the company’s long-term commitment to minimally invasive innovation and surgeon-driven design.

“This launch is a defining milestone for Wenzel Spine,” said William Wilson, CEO of Wenzel Spine. “Our team has spent nearly two decades perfecting expandable device design, and panaSIa brings that legacy to a new clinical segment. We are proud to offer providers a differentiated, minimally invasive solution that transforms SI joint fusion with precision, control, and speed.”

Related posts

BenevolentAI Proposes Delisting via Merger with Osaka Holdings

Business Wire

Ikonisys Wins U.S. Patent for Automated Cancer Treatment Analysis

Business Wire

Factor 7 Medical Expands Leadership, Enhances MedTech Services

Business Wire